2. Search Result
Search Result
Results for "

immunostimulant

" in MedChemExpress (MCE) Product Catalog:

36

Inhibitors & Agonists

1

Biochemical Assay Reagents

1

Peptides

9

Inhibitory Antibodies

4

Natural
Products

6

Isotope-Labeled Compounds

4

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P990074
    Enlonstobart

    SG-001

    		 PD-1/PD-L1 Inflammation/Immunology
    Enlonstobart is a human immunoglobulin G4-kappa, anti-PDCD1 monoclonal antibody. Enlonstobart is an immunostimulant and antineoplastic .
    Enlonstobart
  • HY-P990048
    Muzastotug

    		CTLA-4 Cancer
    Muzastotug is a humanized immunoglobulin G1-kappa, anti-CTLA4 monoclonal antibody. Muzastotug is an immunostimulant and antineoplastic .
    Muzastotug
  • HY-P990092
    Rolistobart

    		Transmembrane Glycoprotein Cancer
    Rolistobart is a humanized immunoglobulin G4-kappa, anti-LILRB4/CD85k monoclonal antibody. Rolistobart is an immunostimulant and antineoplastic .
    Rolistobart
  • HY-147295
    Odetiglucan

    BTH 1677; Imprime PGG

    		 Toll-like Receptor (TLR) Inflammation/Immunology Cancer
    Odetiglucan is a novel β-glucan that is a potent immunostimulant and a Dectin-1 (CLEC7A) agonist. Odetiglucan activates innate immune effector cells and triggers a coordinated anti-cancer immune response .
    Odetiglucan
  • HY-101589
    Sotirimod

    R850

    		 Others Inflammation/Immunology
    Sotirimod is an immunostimulant, and can potentially treat for actinic keratosis.
    Sotirimod
  • HY-119218
    LH 1

    		Others Inflammation/Immunology
    LH 1 is a potent immunostimulant used for the anti-PVP (polyvinylpyrrolidone) response in athymic mice .
    LH 1
  • HY-N2940
    Bisandrographolide A

    BAA

    		 TRP Channel Cardiovascular Disease Inflammation/Immunology
    Bisandrographolide A (BAA) activates TRPV4 channel with an EC50 of 790-950 nM. Bisandrographolide A can bind to CD81 and suppress its function. Bisandrographolide A is an anti-inflammatory, immunostimulant, and antihypertensive compound .
    Bisandrographolide A
  • HY-P991113
    Abazistobart

    		PD-1/PD-L1 Inflammation/Immunology Cancer
    Abazistobart is an immunostimulant and antineoplastic agent targeting the programmed cell death protein 1 (PDCD1). Abazistobart is a chimeric and humanized monoclonal antibody that specifically binds to PDCD1 to block the relevant signaling pathway, thereby activating the immune system and exerting antineoplastic activity. Abazistobart is promising for research of cancers .
    Abazistobart
  • HY-P990080
    Sovipostobart

    		CTLA-4 Cancer
    Sovipostobart is an immunoglobulin G1-kappa, anti-CTLA-4 human monoclonal antibody with cleavable prodomain. Sovipostobart is an immunostimulant and antineoplastic .
    Sovipostobart
  • HY-168159
    TLR7 agonist 27

    		Toll-like Receptor (TLR) NOD-like Receptor (NLR) Inflammation/Immunology
    TLR7 agonist 27 (compound 24) is a potent TLR7 agonist with an EC50 of 238.1 nM. TLR7 agonist 27 shows weak agonistic activity against NOD2 (nucleotide-binding oligomerization domain 2) (EC50 of 6.2 μM). TLR7 agonist 27 is a potent immunostimulant, and can be used as a vaccine adjuvant and/or immunotherapeutic .
    TLR7 agonist 27
  • HY-W250152
    Polycytidylic acid potassium

    		Biochemical Assay Reagents Inflammation/Immunology
    Polycytidylic acid potassium is an immunostimulant and synthetic double-stranded RNA. Polycytidylic acid potassium can be used experimentally to model viral infections in vivo. Polycytidylic acid potassium is a common tool in immune system research .
    Polycytidylic acid potassium
  • HY-13743
    Roquinimex

    Linomide; FCF89; ABR212616

    		 TNF Receptor Inflammation/Immunology
    Roquinimex (Linomide; PNU212616; ABR212616) is a quinoline derivative immunostimulant which increases NK cell activity and macrophage cytotoxicity; inhibits angiogenesis and reduces the secretion of TNF alpha.
    Roquinimex
  • HY-B2149
    Quadrol

    N,N,N′,N′-Tetrakis(2-hydroxypropyl)ethylenediamine; EDTP

    		 Calcium Channel Inflammation/Immunology
    Quadrol is an immunostimulant that has been considered as a potentially useful active molecule for accelerating wound healing. Quadrol can form a complex with Ca 2+, mediate the entry of Ca 2+ into macrophages, and stimulate macrophage activation.
    Quadrol
  • HY-P990072
    Lipustobart

    LZM-009

    		 PD-1/PD-L1 Cancer
    Lipustobart is an IgG4-kappa, anti-PDCD1 (programmed cell death 1, PD1, PD-1, CD279) humanized monoclonal antibody. Lipustobart shows immunostimulant and antineoplastic activity .
    Lipustobart
  • HY-P990014
    Danburstotug

    IMC-001; STI-3031

    		 PD-1/PD-L1 Inflammation/Immunology Cancer
    Danburstotug (IMC-001) is an IgG1-lambda anti-CD274 (PDL1, B7 homologue 1, B7H1) human monoclonal antibody. Danburstotug also is immunostimulant and antineoplastic .
    Danburstotug
  • HY-P990068
    Perenostobart

    SRF617

    		 NTPDase Inflammation/Immunology Cancer
    Perenostobart (SRF617) is a human IgG4 antibody with inhibitory activity against CD39 ATPase. Perenostobart inhibits CD39-mediated hydrolysis of extracellular ATP to AMP, with IC50 values of 1.9 nM (HEK293 OE cells), 0.7 nM (MOLP-8 cells), and 1.2 nM (RBC-lysed whole blood). Perenostobart enhances CD4 + T-cell proliferation, promotes dendritic cell maturation, and boosts inflammasome activation in macrophages in the presence of ATP. Perenostobart demonstrates significant single-agent anti-tumor efficacy in MOLP-8 and H520 xenograft models. Perenostobart can be used for the study of cancer .
    Perenostobart
  • HY-N15770
    VSA 2

    		Biochemical Assay Reagents Inflammation/Immunology
    VSA 2, a saponin-based vaccine adjuvant, is a derivative of Momordica saponin (MS) II. VSA 2 is an immunostimulant, shows consistent enhancement of immunoglobulin G2a (IgG2a) production when it was in formulation with either ovalbumin or recombinant hemagglutinin B (rHagB) antigen .
    VSA 2
  • HY-P1610
    Asudemotide

    		PD-1/PD-L1 Cancer
    Asudemotide (S-588410) is a peptide of human DEP domain-containing protein 1A. Asudemotide is an immunostimulant. Asudemotide has a sequence of H-Glu-Tyr-Tyr-Glu-Leu-Phe-Val-Asn-Ile-OH. Asudemotide induces a tumor immune response in esophageal cancer. .
    Asudemotide
  • HY-10046
    Plerixafor
    Maximum Cited Publications
    88 Publications Verification

    AMD 3100; JM3100; SID791

    		 CXCR HIV Infection Inflammation/Immunology Endocrinology Cancer
    Plerixafor (AMD 3100) is a selective CXCR4 antagonist with an IC50 of 44 nM. Plerixafor, an immunostimulant and a hematopoietic stem cell (HSC) mobilizer, is an allosteric agonist of CXCR7. Plerixafor inhibits HIV-1 and HIV-2 replication with an EC50 of 1-10 nM .
    Plerixafor
  • HY-P991727
    Zamristobart

    		Human leukocyte immunoglobulin (Ig)-like receptors (LILR) Inflammation/Immunology Cancer
    Zamristobart is an anti-LILRB1 (leukocyte immunoglobulin-like receptor B1) IgG4κ type humanized antibody with immunostimulant and antineoplastic activities. The recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
    Zamristobart
  • HY-B0944
    Pidotimod
    1 Publications Verification

    		 Bacterial Inflammation/Immunology
    Pidotimod is an orally active dipeptide immunostimulant with immunomodulatory properties on the adaptive and the innate immune responses. Pidotimod increases macrophage activity and humoral immune functions. Pidotimod can be used for the research of chronic bronchitis, chronic obstructive pulmonary disease (COPD), bronchiectasis, and chronic idiopathic urticaria,et al .
    Pidotimod
  • HY-159754
    HS201

    		Toll-like Receptor (TLR) Inflammation/Immunology
    HS201 is a vaccine adjuvant and a key component in vaccines. Adjuvants can be divided into immunostimulants and delivery systems. Adjuvants can not only enhance the intensity and durability of immune responses, but also affect the type of immune responses. On the one hand, immunostimulants promote the production of antigen signals and co-stimulatory signals by targeting Toll-like receptors (TLRs) and other pattern recognition receptors (PRRs), leading to the maturation and activation of antigen presenting cells (APCs), thereby enhancing adaptive immune responses; on the other hand, delivery systems are carrier materials that promote antigen delivery by prolonging the bioavailability of loaded antigens and targeting antigens to lymph nodes or APCs. Several common adjuvants include: saponins, TLRs agonists, polysaccharides, nanoparticles, cytokines, and mucosal adjuvants .
    HS201
  • HY-159753
    HS105

    		Toll-like Receptor (TLR) Inflammation/Immunology
    HS105 is a vaccine adjuvant and a key component in vaccines. Adjuvants can be divided into immunostimulants and delivery systems. Adjuvants can not only enhance the intensity and durability of immune responses, but also affect the type of immune responses. On the one hand, immunostimulants promote the production of antigen signals and co-stimulatory signals by targeting Toll-like receptors (TLRs) and other pattern recognition receptors (PRRs), leading to the maturation and activation of antigen presenting cells (APCs), thereby enhancing adaptive immune responses; on the other hand, delivery systems are carrier materials that promote antigen delivery by prolonging the bioavailability of loaded antigens and targeting antigens to lymph nodes or APCs. Several common adjuvants include: saponins, TLRs agonists, polysaccharides, nanoparticles, cytokines, and mucosal adjuvants .
    HS105
  • HY-159751
    HS101

    		Toll-like Receptor (TLR) Inflammation/Immunology
    HS101 is a vaccine adjuvant and a key component in vaccines. Adjuvants can be divided into immunostimulants and delivery systems. Adjuvants can not only enhance the intensity and durability of immune responses, but also affect the type of immune responses. On the one hand, immunostimulants promote the production of antigen signals and co-stimulatory signals by targeting Toll-like receptors (TLRs) and other pattern recognition receptors (PRRs), leading to the maturation and activation of antigen presenting cells (APCs), thereby enhancing adaptive immune responses; on the other hand, delivery systems are carrier materials that promote antigen delivery by prolonging the bioavailability of loaded antigens and targeting antigens to lymph nodes or APCs. Several common adjuvants include: saponins, TLRs agonists, polysaccharides, nanoparticles, cytokines, and mucosal adjuvants .
    HS101
  • HY-W008634
    Bropirimine
    2 Publications Verification

    U-54461; U-54461S; PNU-54461

    		 Toll-like Receptor (TLR) Cancer
    Bropirimine (U-54461; U-54461S; PNU-54461) is an orally active TLR7 agonist. Bropirimine inhibits RANKL-induced osteoclast differentiation of mouse bone marrow-derived macrophages (BMMs). Bropirimine exhibits dose-dependent direct inhibitory effects on colony formation of cultured KK-47 and 724 cells. Bropirimine can be used for the study of cancers and bone metabolic disorders such as osteoporosis .
    Bropirimine
  • HY-B1044
    Idramantone

    Kemantane; 5-Hydroxy-2-adamantanone

    		 Drug Derivative Neurological Disease Inflammation/Immunology
    Idramantone (Kemantane, 5-Hydroxy-2-adamantanone) is an Adamantane derivative. Idramantone is an immunostimulant. Idramantone is a versatile starting material for the synthesis of various adamantine deivatives. Idramantone can be produced using P450cam monooxygenase coupled with NADH regeneration as an oxidation biocatalyst. Idramantone can be studied in research on bronchial pathology .
    Idramantone
  • HY-10046S
    Plerixafor-d4

    		Isotope-Labeled Compounds CXCR HIV Infection Inflammation/Immunology Endocrinology Cancer
    Plerixafor-d4 is the deuterium labeled Plerixafor. Plerixafor (AMD 3100) is a selective CXCR4 antagonist with an IC50 of 44 nM. Plerixafor, an immunostimulant and a hematopoietic stem cell (HSC) mobilizer, is an allosteric agonist of CXCR7. Plerixafor inhibits HIV-1 and HIV-2 replication with an EC50 of 1-10 nM .
    Plerixafor-d4
  • HY-10046R
    Plerixafor (Standard)

    AMD 3100 (Standard); JM3100 (Standard); SID791 (Standard)

    		 Reference Standards CXCR HIV Infection Inflammation/Immunology Endocrinology Cancer
    Plerixafor (Standard) is the analytical standard of Plerixafor. This product is intended for research and analytical applications. Plerixafor (AMD 3100) is a selective CXCR4 antagonist with an IC50 of 44 nM. Plerixafor, an immunostimulant and a hematopoietic stem cell (HSC) mobilizer, is an allosteric agonist of CXCR7. Plerixafor inhibits HIV-1 and HIV-2 replication with an EC50 of 1-10 nM .
    Plerixafor (Standard)
  • HY-B0944R
    Pidotimod (Standard)

    		Reference Standards Bacterial Inflammation/Immunology
    Pidotimod (Standard) is the analytical standard of Pidotimod. This product is intended for research and analytical applications. Pidotimod is an orally active dipeptide immunostimulant with immunomodulatory properties on the adaptive and the innate immune responses. Pidotimod increases macrophage activity and humoral immune functions. Pidotimod can be used for the research of chronic bronchitis, chronic obstructive pulmonary disease (COPD), bronchiectasis, and chronic idiopathic urticaria,et al .
    Pidotimod (Standard)
  • HY-128753
    D-Lyxose

    		Endogenous Metabolite Drug Intermediate Metabolic Disease
    D-Lyxose is an endogenous metabolite. D-Lyxose is a rare pentose sugar with significant potential for drug synthesis. D-Lyxose can be used as a starting material for anti-tumor drugs such as alpha galactose ceramide immunostimulants. D-Lyxose can be used as a precursor for L-nucleoside analogs for the development of antiviral drugs. D-Lyxose can be used as a synthetic intermediate for other rare sugars such as L-ribose .
    D-Lyxose
  • HY-128753S6
    D-Lyxose-d

    		Isotope-Labeled Compounds Endogenous Metabolite Drug Intermediate Metabolic Disease
    D-Lyxose-d is the deuterium labeled D-Lyxose. D-Lyxose is an endogenous metabolite. D-Lyxose is a rare pentose sugar with significant potential for drug synthesis. D-Lyxose can be used as a starting material for anti-tumor drugs such as alpha galactose ceramide immunostimulants. D-Lyxose can be used as a precursor for L-nucleoside analogs for the development of antiviral drugs. D-Lyxose can be used as a synthetic intermediate for other rare sugars such as L-ribose .
    D-Lyxose-d
  • HY-128753S7
    D-Lyxose-d-1

    		Isotope-Labeled Compounds Endogenous Metabolite Drug Intermediate Metabolic Disease
    D-Lyxose-d-1 is the deuterium labeled D-Lyxose. D-Lyxose is an endogenous metabolite. D-Lyxose is a rare pentose sugar with significant potential for drug synthesis. D-Lyxose can be used as a starting material for anti-tumor drugs such as alpha galactose ceramide immunostimulants. D-Lyxose can be used as a precursor for L-nucleoside analogs for the development of antiviral drugs. D-Lyxose can be used as a synthetic intermediate for other rare sugars such as L-ribose .
    D-Lyxose-d-1
  • HY-128753S3
    D-Lyxose-13C-2

    		Isotope-Labeled Compounds Endogenous Metabolite Drug Intermediate Others
    D-Lyxose- 13C-2 is the 13C labeled D-Lyxose. D-Lyxose is an endogenous metabolite. D-Lyxose is a rare pentose sugar with significant potential for drug synthesis. D-Lyxose can be used as a starting material for anti-tumor drugs such as alpha galactose ceramide immunostimulants. D-Lyxose can be used as a precursor for L-nucleoside analogs for the development of antiviral drugs. D-Lyxose can be used as a synthetic intermediate for other rare sugars such as L-ribose .
    D-Lyxose-13C-2
  • HY-128753S5
    D-Lyxose-13C-4

    		Isotope-Labeled Compounds Endogenous Metabolite Drug Intermediate Others
    D-Lyxose- 13C-4 is the 13C labeled D-Lyxose. D-Lyxose is an endogenous metabolite. D-Lyxose is a rare pentose sugar with significant potential for drug synthesis. D-Lyxose can be used as a starting material for anti-tumor drugs such as alpha galactose ceramide immunostimulants. D-Lyxose can be used as a precursor for L-nucleoside analogs for the development of antiviral drugs. D-Lyxose can be used as a synthetic intermediate for other rare sugars such as L-ribose .
    D-Lyxose-13C-4
  • HY-128753R
    D-Lyxose (Standard)

    		Reference Standards Endogenous Metabolite Drug Intermediate Metabolic Disease
    D-Lyxose (Standard) is the analytical standard of D-Lyxose. This product is intended for research and analytical applications. D-Lyxose is an endogenous metabolite. D-Lyxose is a rare pentose sugar with significant potential for drug synthesis. D-Lyxose can be used as a starting material for anti-tumor drugs such as alpha galactose ceramide immunostimulants. D-Lyxose can be used as a precursor for L-nucleoside analogs for the development of antiviral drugs. D-Lyxose can be used as a synthetic intermediate for other rare sugars such as L-ribose .
    D-Lyxose (Standard)
  • HY-128753S4
    D-Lyxose-13C-3

    		Isotope-Labeled Compounds Endogenous Metabolite Drug Intermediate Others
    D-Lyxose- 13C-3 is the 13C labeled D-Lyxose. D-Lyxose is an endogenous metabolite. D-Lyxose is a rare pentose sugar with significant potential for drug synthesis. D-Lyxose can be used as a starting material for anti-tumor drugs such as alpha galactose ceramide immunostimulants. D-Lyxose can be used as a precursor for L-nucleoside analogs for the development of antiviral drugs. D-Lyxose can be used as a synthetic intermediate for other rare sugars such as L-ribose .
    D-Lyxose-13C-3

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: